Stemline Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-08-01
- Employees
- 100
- Market Cap
- -
- Website
- http://www.stemline.com
A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02667873
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialist, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02661022
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Dana Farber Cancer Institue, Boston, Massachusetts, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02650817
- Locations
- 🇧🇪
UZ Leuven Campus Gasthuisberg, Leuven, Belgium
🇳🇱Erasmus Medical Center, Rotterdam, Netherlands
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02338349
- Locations
- 🇺🇸
Radius Pharmaceuticals, Inc., Waltham, Massachusetts, United States
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02270463
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Tagraxofusp (SL-401) in Patients With CMML or MF
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02268253
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT02113982
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Presbyterian Shady Side, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸H. Lee Moffiitt Cancer Center & Research Institute, Tampa, Florida, United States
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02078648
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States